Patients and Caregivers

Denali is committed to partnering with patients to discover and develop new, effective therapies for neurodegenerative diseases.

Before a new therapy can be made available to the general public, multiple studies involving healthy volunteers and patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

AREAS OF INTEREST

PRIVACY POLICY AND TERMS OF USE
Please read our
Privacy Policy
and
Terms of Use
to understand how we protect your privacy and how we may collect, use, and share information. At this time, Denali is only collecting information from residents of the United States. PLEASE DO NOT PROVIDE INFORMATION ON THE FORM BELOW IF YOU ARE NOT A UNITED STATES RESIDENT. We make no representation that the Website is appropriate or available for use outside of the United States.

* Required information

If you would like to opt-out of receiving Denali updates from us, please contact us.

POLICY ON EXPANDED ACCESS TO INVESTIGATIONAL DRUGS

Denali understands that there are some cases when a patient is unable to participate in a clinical trial, and other treatment options have been exhausted. In those cases, the patient's physician may choose to request access to an investigational drug outside of a clinical trial via what is termed Expanded Access in the United States.

Currently, participation in clinical trials is the only way for patients to gain access to Denali's investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.